Abiopharma

🔍 Zecca John (Executive)

Company: NASDAQ, INC. (NDAQ)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 7,339 shares of Common Stock, par value $0.01 per share (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: false | shares_owned_after: 156,211.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,097 shares of Common Stock, par value $0.01 per share at $84.89 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: false | shares_owned_after: 154,114.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: Represents an award of Restricted Stock Units (RSUs) granted pursuant to the Issuer's Equity Incentive Plan. Each unit represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest with respect to 33% of the RSUs on April 1, 2028, 33% on April 1, 2029, and the remainder on April 1, 2030.
• F2: Represents shares of Common Stock withheld for taxes in connection with the settlement of an equity award previously granted under the Issuer's Equity Incentive Plan.
• F3: Represents (i) 27,513 shares or units of restricted stock, of which 4,158 are vested and (ii) 126,601 shares of Common Stock underlying PSUs, 118,575 of which are vested.